{"id":"W1496017371","doi":"","title":"Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies.","year":2013,"lang":"en","type":"article","venue":"PubMed","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"ca_institutions":"Bausch Health (Canada)","funders":"","keywords":"Medicine; Imiquimod; Actinic keratosis; Tolerability; Scalp; Placebo; Dermatology; Adverse effect; Clinical endpoint; Randomized controlled trial; Internal medicine; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007196884,0.0003160571,0.001721048,0.00009432988,0.0001733704,0.00003226971,0.00009017926,0.00005102838,0.0000468057],"category_scores_gemma":[0.0004399171,0.0001556484,0.0004669292,0.0001008543,0.0003536344,0.00009548683,0.00004414559,0.0000850495,0.000004046447],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000202337,"about_ca_system_score_gemma":0.00004223247,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000236345,"about_ca_topic_score_gemma":0.00004725254,"domain_scores_codex":[0.9982899,0.0001024091,0.0006046081,0.0003440695,0.0002050733,0.0004539459],"domain_scores_gemma":[0.9956669,0.003223308,0.0003144296,0.0003822956,0.0002731839,0.0001398505],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.895447,0.001055101,0.0009441155,0.00009668658,0.008483805,0.00000345767,0.001874986,0.000003964331,0.00001915314,0.00002124351,0.001543613,0.09050694],"study_design_scores_gemma":[0.9902199,0.0005266871,0.001525533,0.00002642687,0.002483546,0.00000955794,0.000956326,0.0006410367,0.001540865,0.00004103735,0.00188996,0.0001391046],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.920473,0.03567494,0.0001225001,0.002418,0.0005804054,0.03978928,0.00002221921,0.00003912676,0.0008805001],"genre_scores_gemma":[0.8871385,0.006468207,0.0002579006,0.0001455333,0.0003247299,0.1042645,0.000004662508,0.00003066164,0.001365349],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09477299,"threshold_uncertainty_score":0.6347157,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07708493520410008,"score_gpt":0.3597769123377111,"score_spread":0.282691977133611,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}